Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
683 1 |
Ultima descărcare din IBN: 2018-10-31 14:12 |
SM ISO690:2012 LIESNER, Ri J., TSURYA, Valentin. Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study. In: Haemophilia, 2018, nr. 2(24), pp. 211-220. ISSN -. DOI: https://doi.org/ 10.1111/hae.13320 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Haemophilia | ||||||
Numărul 2(24) / 2018 / ISSN - /ISSNe 1351-8216 | ||||||
|
||||||
DOI:https://doi.org/ 10.1111/hae.13320 | ||||||
Pag. 211-220 | ||||||
|
||||||
Vezi articolul | ||||||
Rezumat | ||||||
Introduction: Nuwiq® (Human-cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein fusion. No inhibitors developed in studies with Nuwiq® in 201 previously treated patients with haemophilia A (HA). The immunogenicity, efficacy and safety of Nuwiq® in previously untreated patients (PUPs) with severe HA are being assessed in the ongoing NuProtect study. Methods: The study, conducted across 38 centres worldwide, is evaluating 110 true PUPs of all ages and ethnicities enrolled for study up to 100 exposure days (EDs) or 5 years maximum. The primary objective is to assess the immunogenicity of Nuwiq® (inhibitor activity ≥0.6 BU) using the Nijmegen-modified Bethesda assay at a central laboratory. Results: Data for 66 PUPs with ≥20 EDs from a preplanned interim analysis were analysed. High-titre (HT) inhibitors developed in 8 of 66 patients after a median of 11.5 EDs (range 6-24). Five patients developed low-titre inhibitors (4 transient). The cumulative incidence (95% confidence interval) was 12.8% (4.5%, 21.2%) for HT inhibitors and 20.8% (10.7%, 31.0%) for all inhibitors. During inhibitor-free periods, median annualized bleeding rates during prophylaxis were 0 for spontaneous bleeds and 2.40 for all bleeds. Efficacy was rated as “excellent” or “good” in treating 91.8% of bleeds. Efficacy of surgical prophylaxis was “excellent” or “good” for 8 (89%) procedures and “moderate” for 1 (11%). No tolerability concerns were evident. Conclusion: These interim data show a cumulative incidence of 12.8% for HT inhibitors and convincing efficacy and tolerability in PUPs treated with Nuwiq®. |
||||||
Cuvinte-cheie FVIII inhibitors, haemophilia A, Human-cl rhFVIII, Nuwiq®, previously untreated patients |
||||||
|